Cargando…
Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185574/ https://www.ncbi.nlm.nih.gov/pubmed/21994621 http://dx.doi.org/10.3390/v2102290 |
_version_ | 1782213235698565120 |
---|---|
author | Coughlan, Lynda Alba, Raul Parker, Alan L. Bradshaw, Angela C. McNeish, Iain A. Nicklin, Stuart A. Baker, Andrew H. |
author_facet | Coughlan, Lynda Alba, Raul Parker, Alan L. Bradshaw, Angela C. McNeish, Iain A. Nicklin, Stuart A. Baker, Andrew H. |
author_sort | Coughlan, Lynda |
collection | PubMed |
description | Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” interactions. “Bridging” interactions refer to coagulation factor binding, namely coagulation factor X (FX), which bridges hepatocyte transduction in vivo through engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These interactions can contribute to the off-target sequestration of Ad5 in the liver and its characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various approaches to retargeting adenoviruses (Ad) have been described. These include genetic modification strategies to incorporate peptide ligands (within fiber knob domain, fiber shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with capsid proteins derived from other viral families, hexon hypervariable region (HVR) substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or monoclonal antibodies directed against surface-expressed target antigens. In order to maximize retargeting, strategies which permit detargeting from undesirable interactions between the Ad capsid and components of the circulatory system (e.g. coagulation factors, erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. Detargeting can be achieved by genetic ablation of native receptor-binding determinants, ablation of “bridging interactions” such as those which occur between the hexon of Ad5 and coagulation factor X (FX), or alternatively, through the use of polymer-coated “stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting can be achieved by combining multiple genetic and/or chemical modifications. |
format | Online Article Text |
id | pubmed-3185574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-31855742011-10-12 Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors Coughlan, Lynda Alba, Raul Parker, Alan L. Bradshaw, Angela C. McNeish, Iain A. Nicklin, Stuart A. Baker, Andrew H. Viruses Review Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” interactions. “Bridging” interactions refer to coagulation factor binding, namely coagulation factor X (FX), which bridges hepatocyte transduction in vivo through engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These interactions can contribute to the off-target sequestration of Ad5 in the liver and its characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various approaches to retargeting adenoviruses (Ad) have been described. These include genetic modification strategies to incorporate peptide ligands (within fiber knob domain, fiber shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with capsid proteins derived from other viral families, hexon hypervariable region (HVR) substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or monoclonal antibodies directed against surface-expressed target antigens. In order to maximize retargeting, strategies which permit detargeting from undesirable interactions between the Ad capsid and components of the circulatory system (e.g. coagulation factors, erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. Detargeting can be achieved by genetic ablation of native receptor-binding determinants, ablation of “bridging interactions” such as those which occur between the hexon of Ad5 and coagulation factor X (FX), or alternatively, through the use of polymer-coated “stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting can be achieved by combining multiple genetic and/or chemical modifications. Molecular Diversity Preservation International (MDPI) 2010-10-13 /pmc/articles/PMC3185574/ /pubmed/21994621 http://dx.doi.org/10.3390/v2102290 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Coughlan, Lynda Alba, Raul Parker, Alan L. Bradshaw, Angela C. McNeish, Iain A. Nicklin, Stuart A. Baker, Andrew H. Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors |
title | Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors |
title_full | Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors |
title_fullStr | Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors |
title_full_unstemmed | Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors |
title_short | Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors |
title_sort | tropism-modification strategies for targeted gene delivery using adenoviral vectors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185574/ https://www.ncbi.nlm.nih.gov/pubmed/21994621 http://dx.doi.org/10.3390/v2102290 |
work_keys_str_mv | AT coughlanlynda tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors AT albaraul tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors AT parkeralanl tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors AT bradshawangelac tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors AT mcneishiaina tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors AT nicklinstuarta tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors AT bakerandrewh tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors |